VCYT Earnings Date: Nov 4, 2026 (Estimated) — Veracyte, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is VCYT's next earnings date?
Veracyte, Inc. (VCYT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.41 on revenue of $147.2M.
How did VCYT do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Veracyte, Inc. posted EPS of $0.54 versus the $0.41 estimate, a beat of 31.7%. Revenue was $150.3M against a $144.3M estimate. The stock's 1-day post-earnings move was -22.5%.
How much does VCYT stock move after earnings?
VCYT beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.6% (up or down) in the day after earnings.
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 0.41 | 0.54 | +31.71% | $150.3M | ✅ Beat | -22.52% | -22.80% | -27.50% |
| 2026-05-05 | Q1 2026 | 0.31 | 0.52 | +67.74% | $139.1M | ✅ Beat | +24.93% | +19.99% | +51.47% |
| 2026-02-25 | Q4 2025 | 0.36 | 0.53 | +47.22% | $140.6M | ✅ Beat | +8.48% | +1.54% | -8.17% |
| 2025-11-04 | Q3 2025 | 0.27 | 0.51 | +88.89% | $131.9M | ✅ Beat | +27.46% | +18.11% | +31.26% |
| 2025-08-06 | Q2 2025 | 0.25 | 0.44 | +76.00% | $130.2M | ✅ Beat | +15.48% | +27.99% | +35.29% |
| 2025-05-07 | Q1 2025 | 0.20 | 0.31 | +55.00% | $114.5M | ✅ Beat | +1.20% | -7.62% | -10.96% |
| 2025-02-24 | Q4 2024 | 0.26 | 0.36 | +38.46% | $118.6M | ✅ Beat | -14.99% | -14.74% | -14.41% |
| 2024-11-06 | Q3 2024 | 0.17 | 0.33 | +94.12% | $115.9M | ✅ Beat | +2.05% | +8.04% | +20.61% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $150.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Testing | 96.9% | $145.7M | +19.1% | $219.1M | $107.3M | $122.3M | $127.8M |
| Product | 2.6% | $3.9M | +7.2% | $6.9M | $3.6M | $3.6M | $3.3M |
| Biopharmaceutical And Other | 0.5% | $802K | -81.4% | $7.0M | $3.6M | $4.3M | $1.1M |
By region
Q4 FY24 · $445.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 |
|---|---|---|---|---|
| UNITED STATES | 95.0% | $423.5M | +26.6% | $423.5M |
| Non-US | 5.0% | $22.2M | -16.2% | $22.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.